Product Description
Despite the high prevalence of Autism Spectrum Disorder (ASD), there are no FDA-approved medications for the core symptoms. Furthermore, many of the medications used to treat secondary symptoms of ASD come with significant side effects.1There is emerging evidence that abnormal Nitric Oxide signaling, and the subsequent cellular stress are linked to ASD and may drive the associated symptoms. 2-6Therefore, we aim to target Nitric Oxide signaling in the brain to develop a novel treatment for the core symptoms of ASD. (Sourced from: https://www.neuro-nos.com/science-technology)
Mechanisms of Action: Nitric Oxide Inhibitor
Novel Mechanism: Yes
Modality: Unknown
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: NeuroNos
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Autism Spectrum Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|